リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「The role of surgery for locally recurrent and second recurrent rectal cancer with metastatic disease」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。
リケラボ

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

The role of surgery for locally recurrent and second recurrent rectal cancer with metastatic disease

田中, 綾 名古屋大学

2022.07.01

概要

Background: The role of surgery for locally recurrent rectal cancer (LRRC) with resectable distant metastases or second LRRC remains unclear. This study aimed to clarify the influence of synchronous distant metastases (SDMs), a history of distant metastasis resection (HDMR), and a second LRRC on the outcome.

Methods: The long-term outcomes of 70 surgically treated patients with LRRC between 2006 and 2018 were compared by SDM (n = 10), HDMR (n = 17), and second LRRC (n = 7). Results: Among the 10 patients with SDM, 4 patients underwent simultaneous resection, whereas the other 6 underwent staged resection with distant first approach. Recurrence developed in 9 patients, of which 2 patients with liver re-resection achieved long-term survival without cancer. The patients with and without SDM had equivalent 5-year overall survival rate (40.5% vs. 53.3%, p = 0.519); however, patients with SDM had a worse 3- year recurrence-free survival rate than those without SDM (10.0% vs. 37.5%, p = 0.031). Multivariate analysis showed that primary non-sphincter-preserving surgery, second LRRC, and R1 resection were independent risk factors for overall survival. Similarly, primary non-sphincter-preserving surgery, second LRRC, SDM, and R1 resection were risk factors for recurrence-free survival.

Conclusions: Patients with SDM might still be suitable to undergo salvage surgery and achieve favourable overall survival. Distant metastasectomy should be performed first, followed by a sufficient interval to avoid unnecessary LRRC resection in uncurable patients. An HDMR should not be taken into consideration when making surgical plans. Surgical indication of second LRRC should be strict, especially in referred patients.

論文の公開元へ

この論文で使われている画像

関連論文

関連論文をもっと見る

参考文献

[1] A.J. Breugom, W. van Gijn, E.W. Muller, et al., Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial, Ann. Oncol. 26 (2015) 696–701, https://doi.org/10.1093/annonc/ mdu560.

[2] E. Oki, A. Murata, K. Yoshida, et al., A randomized phase III trial comparing S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC), Ann. Oncol. 27 (2016) 1266–1272, https://doi.org/10.1093/annonc/ mdw162.

[3] K.C. Peeters, C.A. Marijnen, I.D. Nagtegaal, et al., The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma, Ann. Surg. 246 (2007) 693–701, https:// doi.org/10.1097/01.sla.0000257358.56863.ce.

[4] R. Sauer, H. Becker, W. Hohenberger, et al., Preoperative versus postoperative chemoradiotherapy for rectal cancer, N. Engl. J. Med. 351 (2004) 1731–1740, https://doi.org/10.1056/NEJMoa040694.

[5] J.A.W. Hagemans, J.M. van Rees, W.J. Alberda, et al., Locally recurrent rectal cancer; long-term outcome of curative surgical and non-surgical treatment of 447 consecutive patients in a tertiary referral centre, Eur. J. Surg. Oncol. 46 (2020) 448–454, https://doi.org/10.1016/j.ejso.2019.10.037.

[6] C.E. Koh, M.J. Solomon, K.G. Brown, et al., The evolution of pelvic exenteration practice at a single center: lessons learned from over 500 cases, Dis. Colon Rectum 60 (2017) 627–635, https://doi.org/10.1097/DCR.0000000000000825.

[7] H. Ogawa, M. Uemura, J. Nishimura, et al., Preoperative chemoradiation followed by extensive pelvic surgery improved the outcome of posterior invasive locally recurrent rectal cancer without deteriorating surgical morbidities: a retrospective, single-institution analysis, Ann. Surg Oncol. 22 (2015) 4325–4334, https://doi. org/10.1245/s10434-015-4452-0.

[8] H. Iversen, A. Martling, H. Johansson, et al., Pelvic local recurrence from colorectal cancer: surgical challenge with changing preconditions, Colorectal Dis. 20 (2018) 399–406, https://doi.org/10.1111/codi.13966.

[9] M. Tanaka, Y. Kanemitsu, D. Shida, et al., Prognostic impact of intra-abdominal/ pelvic inflammation after radical surgery for locally recurrent rectal cancer, Dis. Colon Rectum 60 (2017) 827–836, https://doi.org/10.1097/ DCR.0000000000000853.

[10] K. Uehara, Z. Ito, Y. Yoshino, A. Arimoto, et al., Aggressive surgical treatment with bony pelvic resection for locally recurrent rectal cancer, Eur. J. Surg. Oncol. 41 (2015) 413–420, https://doi.org/10.1016/j.ejso.2014.11.005.

[11] N.N. Rahbari, A.B. Ulrich, T. Bruckner, et al., Surgery for locally recurrent rectal cancer in the era of total mesorectal excision: is there still a chance for cure? Ann. Surg. 253 (2011) 522–533, https://doi.org/10.1097/SLA.0b013e3182096d4f.

[12] T.G. Bird, S.Y. Ngan, J. Chu, et al., Outcomes and prognostic factors of multimodality treatment for locally recurrent rectal cancer with curative intent, Int. J. Colorectal Dis. 33 (2018) 393–401, https://doi.org/10.1007/s00384-018- 2985-y.

[13] N. Ikoma, Y.N. You, B.K. Bednarski, et al., Impact of recurrence and salvage surgery on survival after multidisciplinary treatment of rectal cancer, J. Clin. Oncol. 35 (2017) 2631–2638, https://doi.org/10.1200/JCO.2016.72.1464.

[14] A. Wibe, M.T. Eriksen, A. Syse, et al., Effect of hospital caseload on long-term outcome after standardization of rectal cancer surgery at a national level, Br. J. Surg. 92 (2005) 217–224, https://doi.org/10.1002/bjs.4821.

[15] G.A. Porter, C.L. Soskolne, W.W. Yakimets, S.C. Newman, Surgeon-related factors and outcome in rectal cancer, Ann. Surg. 227 (1998) 157–167, https://doi.org/ 10.1097/00000658-199802000-00001.

[16] T.E. Read, R.J. Myerson, J.W. Fleshman, et al., Surgeon specialty is associated with outcome in rectal cancer treatment, Dis. Colon Rectum 45 (2002) 904–914, https://doi.org/10.1007/s10350-004-6327-5.

[17] T. Beppu, Y. Sakamoto, K. Hasegawa, et al., A nomogram predicting disease-free survival in patients with colorectal liver metastases treated with hepatic resection: multicenter data collection as a Project Study for Hepatic Surgery of the Japanese Society of Hepato-Biliary-Pancreatic Surgery, J Hepatobiliary Pancreat Sci 19 (2012) 72–84, https://doi.org/10.1007/s00534-011-0460-z.

[18] B. Nordlinger, H. Sorbye, B. Glimelius, et al., Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial, Lancet 371 (2008) 1007–1016, https://doi.org/10.1016/S0140-6736(08)60455-9.

[19] H.S. Park, M. Jung, S.J. Shin, et al., Benefit of adjuvant chemotherapy after curative resection of lung metastasis in colorectal cancer, Ann. Surg Oncol. 23 (2016) 928–935, https://doi.org/10.1245/s10434-015-4951-z.

[20] M. Imanishi, Y. Yamamoto, Y. Hamano, et al., Efficacy of adjuvant chemotherapy after resection of pulmonary metastasis from colorectal cancer: a propensity score- matched analysis, Eur. J. Canc. 106 (2019) 69–77, https://doi.org/10.1016/j. ejca.2018.10.003.

[21] Y. Moriya, K. Uehara, Total pelvic exenteration with distal sacrectomy for fixed locally recurrent rectal cancer, in: V.P. Khatri (Ed.), Atlas of Advanced Operative Surgery, Elsevier Publishers, Philadelphia, 2013, pp. 430–437.

[22] D. Dindo, N. Demartines, P.A. Clavien, Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey, Ann. Surg. 240 (2004) 205–213, https://doi.org/10.1097/01. sla.0000133083.54934.ae.

[23] Y.N. You, J.M. Skibber, C.Y. Hu, et al., Impact of multimodal therapy in locally recurrent rectal cancer, Br. J. Surg. 103 (2016) 753–762, https://doi.org/10.1002/ bjs.10079.

[24] C.A. Harris, M.J. Solomon, A.G. Heriot, et al., The outcomes and patterns of treatment failure after surgery for locally recurrent rectal cancer, Ann. Surg. 264 (2016) 323–329, https://doi.org/10.1097/SLA.0000000000001524.

[25] F.A. Holman, S.J. Bosman, M.G. Haddock, et al., Results of a pooled analysis of IOERT containing multimodality treatment for locally recurrent rectal cancer: results of 565 patients of two major treatment centres, Eur. J. Surg. Oncol. 43 (2017) 107–117, https://doi.org/10.1016/j.ejso.2016.08.015.

[26] D.P. Harji, P.M. Sagar, K. Boyle, et al., Outcome of surgical resection of second- time locally recurrent rectal cancer, Br. J. Surg. 100 (2013) 403–409, https://doi. org/10.1002/bjs.8991.

参考文献をもっと見る

全国の大学の
卒論・修論・学位論文
を
一発検索！

この論文の関連論文を見る